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Abstract
Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) have been defined as events of clinically significant
respiratory deterioration with an unidentifiable cause. They carry a significant mortality and morbidity and while
their exact pathogenesis remains unclear, the possibility remains that hidden infection may play a role. The aim of
this pilot study was to determine whether changes in the respiratory microbiota occur during an AE-IPF. Bacterial
DNA was extracted from bronchoalveolar lavage from patients with stable IPF and those experiencing an AE-IPF. A
hyper-variable region of the 16S ribosomal RNA gene (16S rRNA) was amplified, quantified and pyrosequenced.
Culture independent techniques demonstrate AE-IPF is associated with an increased BAL bacterial burden
compared to stable disease and highlight shifts in the composition of the respiratory microbiota during an AE-IPF.
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Background
Current diagnostic criteria for acute exacerbations of
idiopathic pulmonary fibrosis (AE-IPF) clearly distin-
guish them from exacerbations of other respiratory dis-
eases [1]. Prior to the latest iteration of the guidelines
diagnosis of an AE-IPF specifically required the exclu-
sion of any infective trigger [2]. The exact pathogenesis,
however, remains unknown and it is currently unclear
whether AE-IPF represent an accelerated phase of the
underlying fibroproliferative process or an exaggerated
lung injury response to unidentified preceding or coex-
istent infection [3]. There are a number of factors sup-
porting a role for infection; i) seasonal patterns exist
with increased AE-IPF occurring during the winter
months, ii) respiratory tract infections in individuals
with IPF confer a mortality risk indistinguishable from
that seen with acute exacerbations [4], iii) post mortem
examination in cases of confirmed infection frequently
discloses diffuse alveolar damage identical to that seen
during an AE-IPF and, iv) immunosuppression is associ-
ated with an increased rate of acute exacerbations [5].
Given the limited sensitivity of culture-dependant clin-
ical microbiology techniques it is plausible that many ep-
isodes of apparent AE-IPF arise as the sequelae of
infection [6]. While the role of viruses in AE-IPF has
been extensively investigated [7] there has been little
focus on a potential role for bacteria, despite recent evi-
dence that bacterial burden is increased in the IPF lung
and changes in the microbiome relate to disease out-
comes [8, 9]. In order to explore changes in the bron-
choalveolar lavage (BAL) microbiota during an AE-IPF,
16S rRNA gene qPCR and pyrosequencing were per-




Patients with AE-IPF undergoing bronchoscopy were re-
cruited prospectively from the University of Ulsan,
Korea. A diagnosis of IPF was made, according to inter-
national guidelines [10], following multidisciplinary team
discussion. A diagnosis of an acute exacerbation was
made based on the established criteria at that time [2].
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All subjects with acute exacerbation had negative clinical
evaluation for infection including; respiratory syncytial
virus, influenza A and B, human parainfluenza viruses,
adenovirus, human cytomegalovirus, herpes simplex,
varicella-zoster virus and standard bacterial culture.
Control patients with stable IPF (defined by the absence
of acute exacerbation) were recruited alongside AE-IPF
patients and underwent bronchoscopy at the time of
diagnosis. All bronchoscopies were performed as part of
routine clinical care within the first 48 h of admission
and ideally before the commencement of any antibiotics.
However, a number of AE-IPF subjects did receive anti-
biotics before lavage. Written informed consent was ob-
tained from all subjects and the study received approval
from the local institutional review board.
Bronchoscopy
Fibre-optic bronchoscopy with BAL was performed as
part of routine clinical evaluation, and in subjects under-
going AE-IPF was undertaken within 48 h of admission
to hospital. Bronchoscopy was performed according to a
standard operating procedure [11] and BAL was per-
formed in a single sub-segment of the right middle lobe,
with at least 100 ml of sterile saline instilled. BAL fluid
was examined for the presence of macrophages to con-
firm access of the alveolar compartment, and the ab-
sence of ciliated epithelium was used to exclude large
airway contamination.
DNA extraction
The samples were processed at the time of collection
and subsequently stored at -80 °C as separate cell pellets
and supernatants. The samples, one 2 ml aliquot of BAL
supernatant and one BAL pellet including supernatant,
were thawed and then centrifuged at 20,000 g for
15 min, to pellet cell debris and bacteria. Each pellet was
then re-suspended and combined allowing genomic
DNA to be isolated using the MP Bio FastDNA® SPIN
Kit for Soil (http://www.mpbio.com) as previously de-
scribed [12].
16S rRNA gene qPCR and Pyrosequencing
The V3-V5 region of the bacterial 16S rRNA gene was
amplified using the 357 F forward primer and the 926R
reverse primer for both 16S rRNA gene qPCR and pyro-
sequencing as previously described [12].
Statistical analysis
Analysis was undertaken as described previously [8] with
continuous variables presented as means (± Standard
Deviation [SD]), and categorical variables as proportions.
Metastats was used to perform non-parametric t-test
comparisons of microbial communities between groups,
with P-values corrected by multiple hypotheses testing
using the FDR approach of Benjamini and Hochberg
[13]. We restricted testing to Operational Taxonomic
Units (OTUs) that had a differing mean abundance be-
tween cases and controls of more than 1% of the total.
Shannon’s entropy [14] (alpha diversity index) and
weighted and unweighted UniFrac distances [15] (beta
diversity) were calculated in QIIME. Differences between
subject groups were evaluated with the use of the
Mann–Whitney test for continuous variables and Fish-
er’s exact test for categorical variables. The statistical sig-
nificance of association of variables with an AE-IPF was
assessed using a stepwise backward elimination logistic
regression process to select among potential covariates
for inclusion in the final model. All analyses were per-
formed with the use of SPSS (version 21) and R (http://
cran.r-project.org/). A two-sided P value of less than
0.05 was considered to indicate statistical significance.
Results
Twenty patients with acute exacerbations of IPF and 15
matched control patients with stable IPF were enrolled
at the University of Ulsan in Seoul, Korea (Table 1) [7].
The patients were matched for age, sex, smoking history
and baseline lung function. There was no significant dif-
ference in the use of immunosuppressive therapy be-
tween groups. Patients had negative lavage bacterial
culture and respiratory virus screens. There was no sig-
nificant difference in lavage cell count between either
group. There was a significantly higher neutrophil count
in the lavage of AE-IPF subjects compared to controls
(23.7 ± 4.39 vs. 9.0 ± 3.27; P = 0.037) that occurred at the
expense of monocytes (40.9 ± 3.73 vs. 70.3 ± 3.73; P =
<0.005). There was no significant difference in the
lymphocyte, basophil or eosinophil cell populations. The
average survival in the AE-IPF cohort was 187 (±65)
days compared to 568 (±70) days in the controls (P =
0.0004). Thirteen (65%) of the subjects experiencing an
exacerbation died in the following 60 days and six pa-
tients received mechanical ventilation.
All 35 samples yielded genomic DNA and underwent
amplification of the V3-V5 region of the 16S rRNA gene.





Age (yr) 66.7 (±6.4) 66.3 (±6.7)
Female Sex - number (%) 3 (20%) 5 (25%)
Smoking (Ever v Never) - number (%) 11 (73%) 15 (75%)
FVC - % 79.0 (±21) 80.0 (±19)
DLCO - % 69.0 (±14) 66.0 (±16)
Details are provided for stable IPF and for AE-IPF cases. All lung function data was
recorded when stable. There were no significant differences between either
cohort. Data are mean ± Standard Deviation. DLCO, carbon monoxide diffusion
capacity; FVC, forced vital capacity
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Three of the samples (two exacerbation samples and one
stable sample) yielded insufficient 16S rRNA gene prod-
uct to undergo pyrosequencing and were therefore ex-
cluded. All of the samples in this study were extracted,
amplified and sequenced together in a single batch, to
control for the potential effects of batch and operator
variability. Sequence data has been submitted to the
European Nucleotide Archive and is available under ac-
cession number PRJEB18649 (http://www.ebi.ac.uk/ena/
data/view/PRJEB18649). In addition the denoised reads,
OTU table and clinical data are available to download
from the EMBL-EBI BioStudies database under acces-
sion number S-BSST12 (https://www.ebi.ac.uk/biostu-
dies/studies/S-BSST12).
AE-IPF subjects had on average 4.9×109 (SD ± 7.9 ×
109) copies of the 16S rRNA gene per ml of BAL. This
was over four times higher than the copy number in the
stable IPF subjects (P = 0.012) (Fig. 1). Negative control
samples yielded a bacterial burden close to or below the
lower limit of qPCR quantification (1,000 copies/ml).
Bacterial burden remained significantly associated with a
diagnosis of AE-IPF, using a stepwise logistic regression
incorporating sex, age and smoking status (P = 0.029, R2
0.51) and correlated strongly with disease state (Spear-
man’s ρ = 0.45, P = 0.008), indicating that total bacterial
load is significantly associated with an AE-IPF.
At phylum level the microbiota of the stable IPF sub-
jects was dominated by Firmicutes (34%), Proteobacteria
(32%), Bacteroidetes (16%) and Actinobacteria (10%). Al-
though the same phyla predominated in the AE-IPF sub-
jects, Proteobacteria accounted for over 40% of the total
reads (P = 0.12), with the percentage of reads assigned to
Firmicutes, Bacteroidetes, and Actinobacteria dropping
compared to the stable subjects (29, 14 and 6%
Fig. 1 Bacterial load in acute exacerbation of IPF compared with stable disease
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respectively) (Fig. 2). Comparison at an OTU level iden-
tified that within the Proteobacteria phylum there was a
higher relative abundance of two potentially pathogenic
OTUs in the AE-IPF samples; Campylobacter sp. (P =
0.02) and Stenotrophomonas sp. (P = 0.03). By contrast,
significantly higher numbers of a Veillonella sp. (P <
0.01) were present in the stable IPF samples. Han and
colleagues [16] found both Streptococcus and Staphylo-
coccus OTUs to be associated with IPF disease progres-
sion. Here we do not find any significant difference in
the proportion of either species between the stable and
exacerbation groups.
Discussion
AE-IPF is associated with an increased BAL bacterial bur-
den compared to stable IPF. The bacterial communities of
the stable Korean IPF subjects were found to contain
Streptococcus, Prevotella, Veillonella, Haemophilus and
Pseudomonas which are all commonly found in the air-
ways of healthy individuals as well as subjects with
asthma, COPD and IPF [8, 9, 12, 17, 18]. Following an
AE-IPF there was a notable change in the microbiota with
an increase in two potentially pathogenic Proteobacterial
OTUs; Campylobacter sp. and Stenotrophomonas sp.,
coupled with a significant decrease in Veillonella sp..
Campylobacter, although best known as a gastrointes-
tinal pathogen, has previously been identified in the re-
spiratory microbiota of individuals with severe COPD.
Its presence in the respiratory microbiota is likely to
arise from silent micro-aspiration of gastric contents and
strengthens the already identified association of reflux
and aspiration with acute exacerbations in a subgroup of
patients [19]. Stenotrophomonas, a Gram-negative bac-
terium, is known to colonise the respiratory tract of
patients with chronic lung disease [18]. It is a potential
respiratory pathogen and although most commonly as-
sociated with intubated and ventilated patients, it is re-
sponsible for respiratory infections in cystic patients and
patients with chronic health conditions.
It is important to note that there are a number of limi-
tations in relation to this study. The very nature of AE-
IPF make them severe and unpredictable events and
therefore microbiological sampling is often difficult and
carries a high morbidity. This is evident by the fact that
six out of 20 AE-IPF subjects in the current study were
intubated at the time of sampling, however, when the
data here were analyzed with these subjects excluded,
the observed differences remained unchanged. These pa-
tients were prospectively recruited and sampled, how-
ever, the microbiome work was retrospective and
bronchoscopy samples were collected out of clinical ne-
cessity within the first 24 h of admission. This was
ideally before the commencement of any antibiotics,
however, a number of AE-IPF subjects did receive antibi-
otics therapy prior to sampling. Despite this antibiotic
therapy there was a significant increase in the bacterial
burden and changes in the microbiota, suggesting that
antibiotic therapy does not completely confound the ob-
served differences associated with exacerbation, as it
might be expected that antibiotics would reduce the bac-
terial burden. Future studies will have to concentrate on
overcoming the challenge of prospective sampling;
something which has yet to be achieved in this rapidly
progressive and often fatal complication of IPF. How-
ever, until we understand the aetiology of these events in
more detail the clinical urge will remain to start empiric
anti-microbial therapy at the earliest opportunity when
managing a patient with an AE-IPF.
There are currently no precise methods of ruling out
upper airway bronchoscopic carry over of bacteria, even
with upper airway samples [20]. In this study the same
protocols, procedures and kit batches were used for stable
and AE-IPF samples, rendering any potential contamin-
ation consistent across comparative groups and therefore
unlikely to have influenced the results. Specifically none of
the OTUs demonstrated a correlation with a lower bacter-
ial burden, which can indicate a contaminant [21] and the
inclusion of negative reagent controls, which yielded bac-
terial burden close to or below the lower limit of qPCR
quantification, also demonstrates that the qPCR results
are not a sampling or processing artefact.
Unlike exacerbations of other respiratory conditions
which are truly acute events, the onset of an exacerba-
tion in IPF is more insidious with a gradual worsening
over days to weeks. Consequently by the time of presen-
tation any triggering viruses may no longer be detect-
able, despite exhaustive searching [22]. Viruses have
been shown to impact the respiratory microbiome,
Fig. 2 Changes in specific bacterial species in acute exacerbations of
IPF compared with stable disease
Molyneaux et al. Respiratory Research  (2017) 18:29 Page 4 of 6
causing changes which persist for weeks, so the differ-
ences identified could represent the consequence of an
unidentified preceding viral insult [12].
Conclusions
In summary differences in specific OTUs and bacterial
burden suggest that bacteria may play a causative role in
some AE-IPF. The apparent translocation of bacteria
usually confined to the gastrointestinal tract also sug-
gests a role for aspiration in the development of acute
exacerbations. This pilot study had a number of limita-
tions and a prospective study with paired samples prior
to and during an exacerbation will be required to test
the hypotheses generated by this data. Nonetheless, our
observations challenge the current paradigm for AE-IPF
and provide a rationale for clinical trials of prophylactic
antibiotics as a strategy to prevent acute exacerbations
in individuals with IPF.
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